Key result
Elevated indoxyl sulfate linked to higher blood pressure in patients with short-sleep insomnia.
Why the study?
Does the objective short sleep duration insomnia phenotype correlate with specific metabolic and microbiota changes linked to high blood pressure?
Observational (n=173)
Does the objective short sleep duration insomnia phenotype correlate with specific metabolic and microbiota changes linked to high blood pressure?
Effect estimate: SBP: β = 0.250; DBP: β = 0.256
p-value: p=SBP: .028; DBP: .030
No takes yet. Share an insight, caveat, or question.
The objective short sleep duration insomnia phenotype is associated with elevated serum indoxyl sulfate, which correlates with both blood pressure and specific gut microbiota, suggesting a potential molecular pathway for increased hypertension risk.
Dai et al. (2025) conducted an observational in Chronic insomnia disorder (n=173). Objective short sleep duration insomnia phenotype (ISSD) vs. Normal sleepers was evaluated on Correlation between serum indoxyl sulfate and blood pressure (SBP: β = 0.250; DBP: β = 0.256, p=SBP: .028; DBP: .030). In patients with the objective short sleep duration insomnia phenotype, serum indoxyl sulfate was positively correlated with systolic (β=0.250, p=0.028) and diastolic (β=0.256, p=0.030) blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: